ArticleFrontiers in pharmacology2026
Adjunctive
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Idiopathic sudden sensorineural hearing loss (ISSNHL) is an acute otologic emergency, and hearing recovery remains highly variable and frequently unsatisfactory. Methods and analysis: This is a single-center, randomized, double-blind, placebo-controlled clinical trial to be conducted at Zhejiang Provincial Hospital of Chinese Medicine. The trial has been registered with the International Traditional Medicine Clinical Trial Registry (ITMCTR2026000919). A total of 258 eligible participants will be randomly assigned in a 1:1 ratio to receive conventional therapy combined with either SCP-oil ear-canal packing or glycerin placebo ear-canal packing for 14 consecutive days. The primary outcome is the study-defined total markedly effective rate of hearing recovery at week 2, defined as the proportion of participants achieving complete recovery or marked improvement, as assessed by pure-tone audiometry. Secondary outcomes include the mean improvement in hearing thresholds across the affected frequencies, the hearing-recovery categories, tinnitus severity measured using the Visual Analog Scale (VAS), depressive symptoms assessed using the Self-Rating Depression Scale (SDS), and sleep quality assessed using the Pittsburgh Sleep Quality Index (PSQI). Efficacy outcomes will be assessed at baseline and week 2, with an additional safety assessment conducted at week 4. Adverse events will be monitored throughout the study. Discussion: This trial will provide evidence on the efficacy, safety, and tolerability of adjunctive SCP-oil ear-canal packing for ISSNHL, including its effects on hearing recovery and patient-reported outcomes. The findings may also inform the design of future multicenter clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.